KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

AbCellera Biologics (ABCL) Long-Term Debt Issuances (2020 - 2024)

AbCellera Biologics filings provide 3 years of Long-Term Debt Issuances readings, the most recent being $3.1 million for Q3 2024.

  • Quarterly Long-Term Debt Issuances fell 52.71% to $3.1 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $14.2 million through Sep 2024, up 115.84% year-over-year, with the annual reading at $872000.0 for FY2021, 94.37% down from the prior year.
  • Long-Term Debt Issuances hit $3.1 million in Q3 2024 for AbCellera Biologics, up from $2.4 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $16.2 million in Q1 2020 and bottomed at -$662000.0 in Q2 2020.
  • Average Long-Term Debt Issuances over 3 years is $3.7 million, with a median of $2.2 million recorded in 2024.
  • Peak annual rise in Long-Term Debt Issuances hit 52.71% in 2024, while the deepest fall reached 52.71% in 2024.
  • AbCellera Biologics' Long-Term Debt Issuances stood at -$26000.0 in 2020, then skyrocketed by 25330.77% to $6.6 million in 2023, then plummeted by 52.71% to $3.1 million in 2024.
  • Per Business Quant, the three most recent readings for ABCL's Long-Term Debt Issuances are $3.1 million (Q3 2024), $2.4 million (Q2 2024), and $2.1 million (Q1 2024).